Nanogen(NASDAQ:NGEN) the Amgen of the Future !!!!!!! - 500 Beiträge pro Seite

[interStock]

Hi Leute

Hier ein kleine Beschreibung von Nanogen:

Overview
Summary:
The NanoChip™ Molecular Biology Workstation, our first product, is an integrated bioassay system that uniquely bridges the gap between early-stage scientific research and actual clinical practice, and delivers exceptionally accurate, versatile, efficient and user-friendly analytic capability. Nanogen`s focus is on translating this genomic data into useful information by providing the tools that simplify genetic research.

Background:
Nanogen, Inc., (NGEN) a publicly traded company founded in 1993, integrates advanced microelectronics and molecular biology into a platform technology with potential commercial applications in the fields of medical diagnostics, biomedical research, genomics, genetic testing and drug discovery. Nanogen`s fully automated system, which incorporates a proprietary semiconductor microchip, provides a flexible tool for the rapid identification and analysis of biomolecules. Through the use of microelectronics, the Company`s technology enables the active movement and concentration of charged molecules to and from designated microlocations, or test sites, on the semiconductor microchip. The Company believes its semiconductor based platform technology provides a low cost, highly efficient, accurate and versatile integrated system that will shift the paradigm from current manual and mechanical methods to microelectronic systems, thereby significantly improving the quality of healthcare.

Ihre Technologie:
Overview

Nanogen has developed the NanoChip™ Molecular Biology Workstation that incorporates a proprietary microchip capable of rapid identification and precise analysis of biological molecules. Most molecules are electrically charged and Nanogen takes advantage of this fact to help researchers quickly and efficiently analyze molecules like deoxyribonucleic acid (DNA).

The NanoChip™ Molecular Biology Workstation is a multi-purpose research tool that allows analysis and processing of the microchip or NanoChip™ cartridge. Researchers in the field of molecular biology and genetics use the workstation to study how genes function (functional genomics) and to understand the correlation between genetic variation and disease.

The NanoChip™ can also be used for human identification, important in the forensics field. Recurring genetic patterns, known as short tandem repeats (STRs), are analyzed in this application.

Future applications in development include analysis of gene expression (determining which genes are turned on or off at any time) and multiplying targeted gene sequences (on-chip amplification) to make analysis of minute amounts of genetic material possible.

Ongoing research and strategic partnerships have enabled Nanogen to continue expanding the capabilities of its core technology. Partners include government agencies, diagnostic companies, private laboratories, and other genomic testing companies. The development of the core technology has fostered innovative spin-off applications, which are being pursued as part of Nanogen`s advanced technology programs. These include biological and non-biological applications as well as micro-sensor technology.

Overview
Nanogen recently began marketing its NanoChip™ Molecular Biology Workstation and its NanoChip™ Cartridge to scientists and genomics laboratories, setting new standards for SNP scoring. Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genetic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, "bridging" the research and clinical diagnostic settings.

Nanogen is a publically traded company listed on the Nasdaq; our symbol is NGEN.

Die Zahlen für Q1
Nanogen Reports 2001 First Quarter Results



SAN DIEGO, CA – April 30, 2001 – Nanogen, Inc. (Nasdaq: NGEN) today announced financial results for the first quarter ended March 31, 2001.


Nanogen’s total revenues for the first quarter ended March 31, 2001 were $2.9 million compared to $2.3 million for the same period in 2000. The Company earned the revenue recognized during the quarter ended March 31, 2001 primarily through sponsored research programs arising from the Company’s corporate alliances and from contracts or grants with government agencies. The revenue recognized during the first quarter ended March 31, 2001 also included product revenue related to sales of the NanoChip™ Molecular Biology Workstation and NanoChip™ cartridges.


Nanogen shipped four NanoChip™ Molecular Biology Workstations during the quarter ended March 31, 2001. The four shipments included one sale recorded as product revenue, two non-title transfer transactions and one sale recorded as sponsored research revenue and funded via a corporate alliance. Title transferring transactions normally result in the recording of full instrument revenue at the time of the transaction, while non-title transferring transactions may spread instrument revenue associated with the transaction, if any, over the life of the agreement.


The sale was to the University Pompeu Fabra, Barcelona, Spain. The University Pompeu Fabra intends to use the NanoChip™ Molecular Biology Workstation to study the human Y chromosome and mitochondrial DNA single nucleotide polymorphism ("SNP") variations among human populations. The University Pompeu Fabra also intends to develop research on the genetic epidemiology of various complex diseases. One of the non-title transferring transactions was a shipment to the Scottish National Blood Transfusion Service ("SNBTS") under a Development Site Agreement. SNBTS will use the Workstation to develop an assay able to detect bacterial contamination prior to delivering blood components. The second non-title transferring transaction was the shipment of an instrument to the Copenhagen University Hospital (Rigshospitalet), a hospital associated with the Herlev University Hospital (KAS Herlev). This shipment was made pursuant to an expansion of an existing Development Site Agreement. Rigshospitalet, which conducts clinical research on genetic epidemiology of multifactorial diseases, will use the second Workstation in connection with the Copenhagen City Heart Study, a cardiovascular study of 10,000 individuals from the general population. The additional sale recorded through funded research was to Aventis Research and Technologies as part of our collaboration to develop gene expression applications on the NanoChip™ system.


The Company’s cash, cash equivalents and short-term investment balance at March 31, 2001 was $87.3 million. Total operating expenses for the first quarter of 2001 were $10.5 million, as compared to $6.5 million for the same period in 2000. The increase in operating expenses for the first quarter of 2001 as compared to the same period in 2000 is primarily due to increased sales and marketing expenses as the Company expanded its sales and marketing organization; as well as an increase in legal expenses related to enhancing Nanogen’s intellectual property portfolio and fees related to patent litigation. The Company anticipates a continuation of these expenditures at this level as the NanoChip™ system launch progresses, the patent portfolio continues to increase, and litigation continues. For the quarter ended March 31, 2001, the Company reported a net loss of $6.3 million or $0.30 per share, compared to a net loss of $3.7 million or $0.20 per share for the same period in 2000.


"During the first quarter of 2001, Nanogen completed the hiring and training of its sales and support team, an important step in building an effective commercial organization," said Howard C. Birndorf, Chairman and Chief Executive Officer. "In addition, we invested considerable efforts in our Development Site customers, increasing their comfort and experience with the NanoChip™ technology. We now have sites using the system for a broad range of genetic-based research, including the fields of oncology, infectious diseases, genetic diseases and drug metabolism. We will continue to support these customers as we learn more about how the NanoChip™ system can be further improved and refined to address our targeted customers and markets. We believe that the combination of feedback and publications from our Development Site customers and the integration and training of the sales and marketing team will begin to be reflected in our sales activity in the second half of 2001."


Highlights for the first quarter, ended March 31, 2001 include:



Initiation of testing for the gene expression application of the NanoChip™ Molecular Biology Workstation at three beta sites


Upgrading of the NanoChip™ loader to use a 384 well format as well as a 96 well format to further lengthen walk-away capabilities


Progress with Aventis in the development of an electronics-based protein kinase screening assay


Award of patent for a novel method of detecting length polymorphisms, including short tandem repeats


Formation of a relationship with American Medical Laboratories, Inc. to obtain comparison studies of the NanoChip™ technology against other companies, and to pursue the development of molecular diagnostic test protocols


"We are pleased with the Company’s progress in its research and development programs during the first quarter, " added Mr. Birndorf. "We have initiated gene expression beta trials and have made substantial progress in kinase screening. We also continue to work with Hitachi to improve our instrumentation, and we have established an important relationship with American Medical Laboratories which we expect to benefit us both technically and commercially."


Webcast of Conference Call

Nanogen management will hold a conference call to discuss first quarter financial results today at 4:30 p.m. Eastern Time. A live webcast is available at http://www.videonewswire.com/NANOGEN/043001/and through a link that is posted on Nanogen’s website at http://www.nanogen.com. A telephone replay of the conference call also will be available for 48 hours at 800-633-8284 (domestic) or 858-812-6440 (international), reservation #18538478. The webcast will be available on Nanogen´s website through May 7, 2001.


Nanogen markets its NanoChip™ Molecular Biology Workstation system to scientists and genomics laboratories, setting new standards for SNP scoring. In addition, Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, and may eventually "bridge" the gap between the research and clinical settings. The Nanogen system is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen’s web site at www.nanogen.com.


For full financial statements please download the pdf file available under Financial Publications


This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company´s NanoChip™ system can be successfully commercialized, whether the patented inventions can be successfully incorporated into commercial products, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether the Company´s collaborations will continue to be funded, and other risks and uncertainties discussed under the caption "Factors That May Affect Results´´ and elsewhere in the Company´s Form 10-K for the year ended December 31, 2000 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements. The Company may, at its discretion, issue additional announcements regarding sales or placements of its NanoChip™ Molecular Biology Workstation as it deems appropriate and as required by law.



www.nanogen.com

[herbertraubvogel]

Ja,ich sehe NANOGEN(zuerst 1999 selbst eingestiegen) als MICROSOFT der Biotechnologie voraus.

Bird of prey